POMDOCTOR Ltd (NASDAQ: POM) Stock Competitors & Peer Comparison
See POM's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for POM and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| POM | $0.93 | +2.20% | 6M | -0.15 | -$6.05 | N/A |
| RPRX | $58.22 | -0.26% | 25.8B | 11.09 | $5.25 | +1.58% |
| CORT | $114.74 | -0.77% | 12.4B | 327.83 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $70.69 | -4.05% | 6.3B | 51.60 | $1.37 | N/A |
| KNSA | $75.73 | -0.49% | 5.8B | 78.07 | $0.97 | N/A |
| PBH | $46.74 | -0.40% | 2.2B | 10.58 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $18.10 | +3.55% | 1.1B | -9.78 | -$1.85 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
POM vs RPRX Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, RPRX has a market cap of 25.8B. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while RPRX trades at $58.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas RPRX's P/E ratio is 11.09. In terms of profitability, POM's ROE is +0.16%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, POM is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for POM.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
POM vs CORT Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, CORT has a market cap of 12.4B. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while CORT trades at $114.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas CORT's P/E ratio is 327.83. In terms of profitability, POM's ROE is +0.16%, compared to CORT's ROE of +0.08%. Regarding short-term risk, POM is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for POM.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
POM vs WBA Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas WBA's P/E ratio is -1.64. In terms of profitability, POM's ROE is +0.16%, compared to WBA's ROE of -0.57%. Regarding short-term risk, POM is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for POM.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
POM vs LQDA Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, LQDA has a market cap of 6.3B. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while LQDA trades at $70.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas LQDA's P/E ratio is 51.60. In terms of profitability, POM's ROE is +0.16%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, POM is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for POM.Check LQDA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
POM vs KNSA Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, KNSA has a market cap of 5.8B. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while KNSA trades at $75.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas KNSA's P/E ratio is 78.07. In terms of profitability, POM's ROE is +0.16%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, POM is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for POM.Check KNSA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
POM vs PBH Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, PBH has a market cap of 2.2B. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while PBH trades at $46.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas PBH's P/E ratio is 10.58. In terms of profitability, POM's ROE is +0.16%, compared to PBH's ROE of +0.09%. Regarding short-term risk, POM is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for POM.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
POM vs HROWL Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas HROWL's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, POM is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for POM.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
POM vs HROWM Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas HROWM's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, POM is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for POM.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
POM vs LTGO Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, LTGO has a market cap of 1.1B. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while LTGO trades at $18.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas LTGO's P/E ratio is -9.78. In terms of profitability, POM's ROE is +0.16%, compared to LTGO's ROE of N/A. Regarding short-term risk, POM is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for POM.Check LTGO's competition here
Cybin Inc. Common Stock (NASDAQ: HELP)
POM vs HELP Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, HELP has a market cap of 787.2M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while HELP trades at $12.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas HELP's P/E ratio is -3.05. In terms of profitability, POM's ROE is +0.16%, compared to HELP's ROE of -0.71%. Regarding short-term risk, POM is more volatile compared to HELP. This indicates higher risk in terms of short-term price fluctuations for POM.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
POM vs SVA Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas SVA's P/E ratio is -5.68. In terms of profitability, POM's ROE is +0.16%, compared to SVA's ROE of -0.01%. Regarding short-term risk, POM is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for POM.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
POM vs CUVL Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, CUVL has a market cap of 294.2M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while CUVL trades at $5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas CUVL's P/E ratio is 12.59. In terms of profitability, POM's ROE is +0.16%, compared to CUVL's ROE of N/A. Regarding short-term risk, POM is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for POM.Check CUVL's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
POM vs CELG-RI Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, CELG-RI has a market cap of 255.1M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, POM is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for POM.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
POM vs HITI Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, HITI has a market cap of 246M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while HITI trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas HITI's P/E ratio is -10.34. In terms of profitability, POM's ROE is +0.16%, compared to HITI's ROE of -0.36%. Regarding short-term risk, POM is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for POM.Check HITI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
POM vs ETRA Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, ETRA has a market cap of 240.8M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while ETRA trades at $11.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas ETRA's P/E ratio is -4.28. In terms of profitability, POM's ROE is +0.16%, compared to ETRA's ROE of N/A. Regarding short-term risk, POM is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for POM.Check ETRA's competition here
Stablecoin Development Corp. (AMEX: SDEV)
POM vs SDEV Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, SDEV has a market cap of 166M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while SDEV trades at $3.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas SDEV's P/E ratio is -0.57. In terms of profitability, POM's ROE is +0.16%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, POM is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for POM.Check SDEV's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
POM vs CTOR Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, CTOR has a market cap of 97.6M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while CTOR trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas CTOR's P/E ratio is -2.23. In terms of profitability, POM's ROE is +0.16%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, POM is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for POM.Check CTOR's competition here
Atlantic International Corp. (NASDAQ: ATLN)
POM vs ATLN Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas ATLN's P/E ratio is -0.68. In terms of profitability, POM's ROE is +0.16%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, POM is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for POM.Check ATLN's competition here
Rite Aid Corporation (NYSE: RAD)
POM vs RAD Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas RAD's P/E ratio is -0.05. In terms of profitability, POM's ROE is +0.16%, compared to RAD's ROE of +2.76%. Regarding short-term risk, POM is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for POM.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
POM vs GLTO Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas GLTO's P/E ratio is -1.78. In terms of profitability, POM's ROE is +0.16%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, POM is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for POM.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
POM vs NSRX Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, NSRX has a market cap of 31M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while NSRX trades at $3.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas NSRX's P/E ratio is -5.01. In terms of profitability, POM's ROE is +0.16%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, POM is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for POM.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
POM vs SCYX Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, SCYX has a market cap of 29.3M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while SCYX trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas SCYX's P/E ratio is -1.36. In terms of profitability, POM's ROE is +0.16%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, POM is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for POM.Check SCYX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
POM vs COSM Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, COSM has a market cap of 22.9M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while COSM trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas COSM's P/E ratio is -0.57. In terms of profitability, POM's ROE is +0.16%, compared to COSM's ROE of -1.19%. Regarding short-term risk, POM is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for POM.Check COSM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
POM vs BFRI Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, BFRI has a market cap of 14M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while BFRI trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas BFRI's P/E ratio is -1.98. In terms of profitability, POM's ROE is +0.16%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, POM is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for POM.Check BFRI's competition here
Cerenome, Inc. (NASDAQ: CNSY)
POM vs CNSY Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, CNSY has a market cap of 12.8M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while CNSY trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas CNSY's P/E ratio is -0.44. In terms of profitability, POM's ROE is +0.16%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, POM is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for POM.Check CNSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
POM vs SCNX Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, SCNX has a market cap of 10.8M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while SCNX trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas SCNX's P/E ratio is -0.13. In terms of profitability, POM's ROE is +0.16%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, POM is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for POM.Check SCNX's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
POM vs CJJD Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas CJJD's P/E ratio is -0.46. In terms of profitability, POM's ROE is +0.16%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, POM is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for POM.Check CJJD's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
POM vs BFRIW Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, BFRIW has a market cap of 8.5M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, POM's ROE is +0.16%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, POM is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for POM.Check BFRIW's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
POM vs SSY Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas SSY's P/E ratio is -2.86. In terms of profitability, POM's ROE is +0.16%, compared to SSY's ROE of -0.09%. Regarding short-term risk, POM is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for POM.Check SSY's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
POM vs BGMS Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, BGMS has a market cap of 4.9M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while BGMS trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas BGMS's P/E ratio is -0.25. In terms of profitability, POM's ROE is +0.16%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, POM is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for POM.Check BGMS's competition here
Eocene Ltd. (NASDAQ: EOCN)
POM vs EOCN Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, EOCN has a market cap of 3.6M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while EOCN trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas EOCN's P/E ratio is -0.25. In terms of profitability, POM's ROE is +0.16%, compared to EOCN's ROE of N/A. Regarding short-term risk, POM is more volatile compared to EOCN. This indicates higher risk in terms of short-term price fluctuations for POM.Check EOCN's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
POM vs PAVS Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, PAVS has a market cap of 3.4M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while PAVS trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas PAVS's P/E ratio is -0.04. In terms of profitability, POM's ROE is +0.16%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, POM is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for POM.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
POM vs MDVL Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas MDVL's P/E ratio is -0.05. In terms of profitability, POM's ROE is +0.16%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, POM is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for POM.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
POM vs ATNFW Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas ATNFW's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, POM is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for POM.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
POM vs BGMSP Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, POM's ROE is +0.16%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, POM is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for POM.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
POM vs AZNH Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas AZNH's P/E ratio is 38.35. In terms of profitability, POM's ROE is +0.16%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, POM is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for POM.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
POM vs LFLYW Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, POM's ROE is +0.16%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, POM is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for POM.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
POM vs PRPH Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, PRPH has a market cap of 140.9K. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas PRPH's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, POM is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for POM.Check PRPH's competition here
Shire plc (NASDAQ: SHPG)
POM vs SHPG Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas SHPG's P/E ratio is 11.35. In terms of profitability, POM's ROE is +0.16%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, POM is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for POM.Check SHPG's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
POM vs ESRX Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas ESRX's P/E ratio is 10.69. In terms of profitability, POM's ROE is +0.16%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, POM is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for POM.Check ESRX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
POM vs IPXL Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas IPXL's P/E ratio is -10.11. In terms of profitability, POM's ROE is +0.16%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, POM is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for POM.Check IPXL's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
POM vs OREX Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, OREX has a market cap of 0. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas OREX's P/E ratio is -0.14. In terms of profitability, POM's ROE is +0.16%, compared to OREX's ROE of -0.54%. Regarding short-term risk, POM is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for POM.Check OREX's competition here
POZEN Inc. (NASDAQ: POZN)
POM vs POZN Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, POZN has a market cap of 0. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas POZN's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to POZN's ROE of +0.61%. Regarding short-term risk, POM is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for POM.Check POZN's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
POM vs CPD Comparison September 2026
POMDOCTOR Ltd (NASDAQ: POM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, POM stands at 6M. In comparison, CPD has a market cap of 0. Regarding current trading prices, POM is priced at $0.93 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
POM currently has a P/E ratio of -0.15, whereas CPD's P/E ratio is N/A. In terms of profitability, POM's ROE is +0.16%, compared to CPD's ROE of N/A. Regarding short-term risk, POM is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for POM.Check CPD's competition here